FDAnews
www.fdanews.com/articles/101329-inhibitex-obtains-hcv-polymerase-inhibitors-license

Inhibitex Obtains HCV Polymerase Inhibitors License

November 20, 2007

Inhibitex has entered into an exclusive worldwide license agreement with the UK’s Cardiff University and Katholieke Universiteit in Belgium covering a series of hepatitis C virus (HCV) polymerase inhibitors in exchange for an upfront license fee, future milestone payments and royalties on future net sales.

The compounds include a series of nucleoside analogs that inhibit NS5b, a critical enzyme in the life cycle of HCV. In vitro studies using a HCV genotype 1b subgenomic replicon system demonstrate these nucleoside analogues are among the most potent HCV polymerase inhibitors in development, Inhibitex said.

Additional financial details were not disclosed.